<p>Marex Group plc 在第二季度收购了 Arrowhead Pharmaceuticals, Inc.（NASDAQ:ARWR - 免费报告）的新股份，根据其最近向证券交易委员会提交的文件。该基金收购了 36,469 股生物技术公司的股票，价值约为 576,000 美元。</p>
<ul>
<li>想要在生物技术领域获得多元化的收益吗？查看 LABU</li>
</ul>
<p>其他一些对冲基金最近也调整了对该公司的持股。Virtus Advisers LLC 在第二季度购买了 Arrowhead Pharmaceuticals 的新股份，价值 34,000 美元。Nisa Investment Advisors LLC 在第二季度将其在 Arrowhead Pharmaceuticals 的持股增加了 75.9%。Nisa Investment Advisors LLC 现在拥有 3,032 股生物技术公司的股票，价值 48,000 美元，在此期间又收购了 1,308 股。大和证券集团在第二季度将其在 Arrowhead Pharmaceuticals 的持股增加了 883.3%。大和证券集团现在拥有 4,189 股生物技术公司的股票，价值 66,000 美元，在此期间又收购了 3,763 股。未来资产全球投资有限公司在第二季度将其在 Arrowhead Pharmaceuticals 的持股增加了 29.5%。未来资产全球投资有限公司现在拥有 5,335 股生物技术公司的股票，价值 84,000 美元，在上个季度又收购了 1,214 股。最后，Lazard Asset Management LLC 在第二季度购买了 Arrowhead Pharmaceuticals 的新股份，价值约为 91,000 美元。对冲基金和其他机构投资者持有该公司 62.61% 的股份。</p>
<h2>分析师评级调整</h2>
<p>一些研究分析师最近对该股票进行了评论。Piper Sandler 将 Arrowhead Pharmaceuticals 的目标价格从 45.00 美元提高至 70.00 美元，并在 11 月 19 日的研究报告中给予该公司 “增持” 评级。摩根士丹利将 Arrowhead Pharmaceuticals 的目标价格从 45.00 美元提高至 48.00 美元，并在 11 月 26 日的报告中给予该公司 “持平” 评级。加拿大皇家银行将 Arrowhead Pharmaceuticals 的目标价格从 52.00 美元提高至 80.00 美元，并在周四的报告中给予该股票 “跑赢大盘” 评级。美国银行将 Arrowhead Pharmaceuticals 的目标价格从 62.00 美元提高至 81.00 美元，并在 12 月 9 日的研究报告中给予该公司 “买入” 评级。最后，Chardan Capital 重申了 “买入” 评级，并在 12 月 1 日的研究报告中对 Arrowhead Pharmaceuticals 的目标价格设定为 60.00 美元。两位分析师给予该股票 “强烈买入” 评级，五位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Arrowhead Pharmaceuticals 的平均评级为 “适度买入”，共识目标价格为 58.56 美元。</p>
<p><strong>查看我们对 Arrowhead Pharmaceuticals 的最新股票分析</strong></p>
<h2>Arrowhead Pharmaceuticals 股价下跌 1.0%</h2>
<p>Arrowhead Pharmaceuticals 的股票在周一开盘价为 70.09 美元。Arrowhead Pharmaceuticals, Inc. 的一年低点为 9.57 美元，一年高点为 72.36 美元。该公司的 50 日移动平均价格为 45.48 美元，200 日移动平均价格为 29.55 美元。该公司的债务与股本比率为 0.43，流动比率为 4.86，速动比率为 4.86。该公司的市值为 95.2 亿美元，市盈率为 -876.02，贝塔值为 1.28。</p>
<h2>Arrowhead Pharmaceuticals 的内部活动</h2>
<p>在其他新闻中，董事 Michael S. Perry 于 12 月 5 日星期五出售了 16,250 股公司的股票。股票以平均价格 61.03 美元出售，总价值为 991,737.50 美元。出售完成后，该董事直接持有 115,240 股公司股票，价值约为 7,033,097.20 美元。此次交易使其持股减少了 12.36%。该出售在向证券交易委员会的文件中披露，可以通过此超链接访问。此外，董事 Mauro Ferrari 于 11 月 28 日星期五出售了 8,750 股公司的股票。股票以平均价格 56.39 美元出售，总交易额为 493,412.50 美元。交易完成后，该董事持有 68,764 股公司股票，价值 3,877,601.96 美元。此次交易使其持股减少了 11.29%。该出售的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士已出售价值 2,185,150 美元的 45,000 股公司股票。公司内部人士持有该公司 4.30% 的股份。</p>
<h2>关于 Arrowhead Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>Arrowhead Pharmaceuticals, Inc. 在美国开发治疗难治性疾病的药物。该公司的产品管线包括 Plozasiran，目前正在进行 2b 期和一项 3 期临床试验，以治疗高甘油三酯血症、混合性血脂异常和乳糜微粒血症；Zodasiran 正在进行 2b 期临床试验，以治疗血脂异常和高甘油三酯血症；ARO-PNPLA3 正在进行 1 期临床试验，以治疗非酒精性脂肪性肝炎患者；ARO-RAGE 正在进行 1/2a 期临床试验，以治疗炎症性肺部疾病；ARO-MUC5AC 正在进行 1/2a 期临床试验，以治疗粘液阻塞性肺病。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 Arrowhead Pharmaceuticals 更好</li>
<li>投资者必须了解的场外（OTC）股票信息</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>3 只金融股票在 10 年期国债收益率上升时值得购买</li>
<li>如何从价值投资中获利</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Arrowhead Pharmaceuticals 吗？</h2>
<p>在你考虑 Arrowhead Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Arrowhead Pharmaceuticals 并不在名单上。</p>
<p>虽然 Arrowhead Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

箭头制药

<p>Marex Group plc 在第二季度收购了 36,469 股 Arrowhead Pharmaceuticals, Inc. 的股票，价值约为 576,000 美元。其他几家对冲基金也调整了在该公司的持股。分析师对 Arrowhead Pharmaceuticals 给予了 “适度买入” 的评级，目标价共识为 58.56 美元。该股票开盘价为 70.09 美元，市值为 95.2 亿美元。最近的内部交易涉及董事 Michael S. Perry 和 Mauro Ferrari 的股票出售</p>

<p>Marex Group plc acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 36,469 shares of the biotechnology company's stock, valued at approximately $576,000.</p>
<div class="lb-trans"><p>Marex Group plc 在第二季度收购了 Arrowhead Pharmaceuticals, Inc.（NASDAQ:ARWR - 免费报告）的新股份，根据其最近向证券交易委员会提交的文件。该基金收购了 36,469 股生物技术公司的股票，价值约为 576,000 美元。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技术领域获得多元化的收益吗？查看 LABU</li>
</ul>
</div><p>A number of other hedge funds also recently modified their holdings of the business. Virtus Advisers LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at $34,000. Nisa Investment Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 75.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 1,308 shares during the period. Daiwa Securities Group Inc. boosted its position in Arrowhead Pharmaceuticals by 883.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company's stock worth $66,000 after acquiring an additional 3,763 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Arrowhead Pharmaceuticals by 29.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock valued at $84,000 after acquiring an additional 1,214 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth approximately $91,000. Hedge funds and other institutional investors own 62.61% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也调整了对该公司的持股。Virtus Advisers LLC 在第二季度购买了 Arrowhead Pharmaceuticals 的新股份，价值 34,000 美元。Nisa Investment Advisors LLC 在第二季度将其在 Arrowhead Pharmaceuticals 的持股增加了 75.9%。Nisa Investment Advisors LLC 现在拥有 3,032 股生物技术公司的股票，价值 48,000 美元，在此期间又收购了 1,308 股。大和证券集团在第二季度将其在 Arrowhead Pharmaceuticals 的持股增加了 883.3%。大和证券集团现在拥有 4,189 股生物技术公司的股票，价值 66,000 美元，在此期间又收购了 3,763 股。未来资产全球投资有限公司在第二季度将其在 Arrowhead Pharmaceuticals 的持股增加了 29.5%。未来资产全球投资有限公司现在拥有 5,335 股生物技术公司的股票，价值 84,000 美元，在上个季度又收购了 1,214 股。最后，Lazard Asset Management LLC 在第二季度购买了 Arrowhead Pharmaceuticals 的新股份，价值约为 91,000 美元。对冲基金和其他机构投资者持有该公司 62.61% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of research analysts recently commented on the stock. Piper Sandler boosted their price objective on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, November 19th. Morgan Stanley boosted their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, November 26th. Royal Bank Of Canada increased their price objective on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday. Bank of America lifted their price objective on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, December 9th. Finally, Chardan Capital reaffirmed a &#34;buy&#34; rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $58.56.</p>
<div class="lb-trans"><p>一些研究分析师最近对该股票进行了评论。Piper Sandler 将 Arrowhead Pharmaceuticals 的目标价格从 45.00 美元提高至 70.00 美元，并在 11 月 19 日的研究报告中给予该公司 “增持” 评级。摩根士丹利将 Arrowhead Pharmaceuticals 的目标价格从 45.00 美元提高至 48.00 美元，并在 11 月 26 日的报告中给予该公司 “持平” 评级。加拿大皇家银行将 Arrowhead Pharmaceuticals 的目标价格从 52.00 美元提高至 80.00 美元，并在周四的报告中给予该股票 “跑赢大盘” 评级。美国银行将 Arrowhead Pharmaceuticals 的目标价格从 62.00 美元提高至 81.00 美元，并在 12 月 9 日的研究报告中给予该公司 “买入” 评级。最后，Chardan Capital 重申了 “买入” 评级，并在 12 月 1 日的研究报告中对 Arrowhead Pharmaceuticals 的目标价格设定为 60.00 美元。两位分析师给予该股票 “强烈买入” 评级，五位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Arrowhead Pharmaceuticals 的平均评级为 “适度买入”，共识目标价格为 58.56 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Arrowhead Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Arrowhead Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Arrowhead Pharmaceuticals Trading Down 1.0%</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 股价下跌 1.0%</h2>
</div><p>Arrowhead Pharmaceuticals stock opened at $70.09 on Monday. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $72.36. The company's fifty day moving average price is $45.48 and its two-hundred day moving average price is $29.55. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. The company has a market capitalization of $9.52 billion, a price-to-earnings ratio of -876.02 and a beta of 1.28.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals 的股票在周一开盘价为 70.09 美元。Arrowhead Pharmaceuticals, Inc. 的一年低点为 9.57 美元，一年高点为 72.36 美元。该公司的 50 日移动平均价格为 45.48 美元，200 日移动平均价格为 29.55 美元。该公司的债务与股本比率为 0.43，流动比率为 4.86，速动比率为 4.86。该公司的市值为 95.2 亿美元，市盈率为 -876.02，贝塔值为 1.28。</p>
</div><h2>Insider Activity at Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 的内部活动</h2>
</div><p>In other news, Director Michael S. Perry sold 16,250 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $61.03, for a total value of $991,737.50. Following the completion of the sale, the director directly owned 115,240 shares in the company, valued at approximately $7,033,097.20. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, Director Mauro Ferrari sold 8,750 shares of the firm's stock in a transaction on Friday, November 28th. The shares were sold at an average price of $56.39, for a total transaction of $493,412.50. Following the completion of the transaction, the director owned 68,764 shares in the company, valued at $3,877,601.96. The trade was a 11.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 45,000 shares of company stock valued at $2,185,150. Corporate insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Michael S. Perry 于 12 月 5 日星期五出售了 16,250 股公司的股票。股票以平均价格 61.03 美元出售，总价值为 991,737.50 美元。出售完成后，该董事直接持有 115,240 股公司股票，价值约为 7,033,097.20 美元。此次交易使其持股减少了 12.36%。该出售在向证券交易委员会的文件中披露，可以通过此超链接访问。此外，董事 Mauro Ferrari 于 11 月 28 日星期五出售了 8,750 股公司的股票。股票以平均价格 56.39 美元出售，总交易额为 493,412.50 美元。交易完成后，该董事持有 68,764 股公司股票，价值 3,877,601.96 美元。此次交易使其持股减少了 11.29%。该出售的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士已出售价值 2,185,150 美元的 45,000 股公司股票。公司内部人士持有该公司 4.30% 的股份。</p>
</div><h2>About Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Arrowhead Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc. 在美国开发治疗难治性疾病的药物。该公司的产品管线包括 Plozasiran，目前正在进行 2b 期和一项 3 期临床试验，以治疗高甘油三酯血症、混合性血脂异常和乳糜微粒血症；Zodasiran 正在进行 2b 期临床试验，以治疗血脂异常和高甘油三酯血症；ARO-PNPLA3 正在进行 1 期临床试验，以治疗非酒精性脂肪性肝炎患者；ARO-RAGE 正在进行 1/2a 期临床试验，以治疗炎症性肺部疾病；ARO-MUC5AC 正在进行 1/2a 期临床试验，以治疗粘液阻塞性肺病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>Earnings Per Share Calculator: How to Calculate EPS</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>How to Profit From Value Investing</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Arrowhead Pharmaceuticals 更好</li>
<li>投资者必须了解的场外（OTC）股票信息</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>3 只金融股票在 10 年期国债收益率上升时值得购买</li>
<li>如何从价值投资中获利</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Arrowhead Pharmaceuticals 吗？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Arrowhead Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Arrowhead Pharmaceuticals 并不在名单上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arrowhead Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Marex Group plc 收购了箭头制药公司 36,469 股股票